Increasing interest has been addressed toward the introduction of new therapeutic
approaches to obtaining continuous dopaminergic stimulation (CDS). The goal of this …

Importance of the field: Despite the fact that Parkinson's disease (PD) was discovered almost
200 years ago, its treatment and management remain immense challenges because …

Adenosine A2a receptor antagonists reduce symptom severity in Parkinson disease (PD)
and animal models. Rodent studies support the hypothesis that A2a antagonists produce …

A pharmaceutical dosage form for the release of at least one pharmaceutically active
ingredient is claimed. The pharmaceutical dosage form includes a polymer matrix, polymer …

During chronic treatment with l-dopa (LD), Parkinsonian patients often experience
uncontrolled motor complications due to fluctuations of the plasmatic levels of LD that result …

Disclosed herein are compositions that include for example the arginine salt of carbidopa,
and methods for treating neu rological or movement diseases or disorders such as restless …

Objective: To compile a comprehensive summary of published human experience with
levodopa given intravenously, with a focus on information required by regulatory agencies …

Disclosed herein are compositions that include for example the arginine salt of carbidopa,
and methods for treating neurological or movement diseases or disorders such as restless …

Provided herein, in part, is a method of treating a neurological or movement disorderina
patient in need thereof, comprising Subcutaneously administering to said patient a …

Rationale: Synaptic dopamine (DA) release induced by amphetamine or other experimental
manipulations can displace [11 C] raclopride (RAC*) from dopamine D2-like receptors. We …